Kornimate/medical-research-clean huggingface dataset:
the moran amd genetic testing assessment study

Conditions: Age-Related Macular Degeneration; Genetic Testing; Nutritional Biomarkers

Summary: the goals of this study are: to assess the impact of genetic testing for age-related macular degeneration (amd) on lifestyle behaviors as measured by systemic and ocular carotenoid status.


Eligibility criteria:
inclusion criteria: * participants must be between 18 and 64 years of age. * they must also be caucasian as this genetic test is only validated in caucasians. * they can have a positive family history of amd but this is not necessary. exclusion criteria: * personal history of amd * non caucasian * employee of the moran or other eye care practice (likely to have more knowledge about amd than a layperson) * personal history of prior genetic testing for amd risk * anticipated cataract surgery in the upcoming year (can affect macular pigment measurement) * major psychiatric disorder
closed-loop synchronization versus conventional synchronization

Conditions: Acute Respiratory Failure; Pediatric Respiratory Distress Syndrome

Summary: a prior research indicated that asynchrony between the patient and ventilator occurred in 33 percent of 19,175 breaths, and was seen in every patient. the most prevalent kind of asynchrony was ineffective triggering (68%), followed by delayed termination (19%), double triggering (4%) and premature termination (3%). asynchrony between the patient and ventilator increased considerably with decreasing levels of peak inspiratory pressure, positive end-expiratory pressure, and set frequency.despite this, more asynchrony categories exist, and there is no widely accepted categorization. major asynchronies, however, include auto trigger, ineffective effort, and double trigger, while minor asynchronies include early/late cycle, trigger delay, and spontaneous breaths during a mandatory breath. this study aims to compare the safety and efficacy of a closed-loop synchronization controller with conventional control of synchronization during invasive mechanical ventilation of spontaneous breathing of pediatric patients in a pediatric intensive care unit (picu).


Eligibility criteria:
inclusion criteria: * pediatric patients older than 1 month and younger than18 years of age * hospitalized at the picu with the intention of treatment with mechanical ventilation at least for the upcoming 3 hours with spontaneous breathing activity * written informed consent signed and dated by the patient or one relative in case that the patient is unable to consent, after full explanation of the study by the investigator and prior to study participation exclusion criteria: * formalized ethical decision to withhold or withdraw life support * patient included in another interventional research study under consent * patient already enrolled in the present study in a previous episode of respiratory failure * pregnant woman * patients deemed at high risk for the need of transportation from picu to another ward, diagnostic unit or any other hospital * hemodynamic instability defined as a need of continuous infusion of epinephrine or norepinephrine \> 1 mg/h * not being able to obtain reference waveform

Keywords: acute respiratory failure (arf) pediatric acute respiratory distress syndrome (pards) closed-loop synchronization patient ventilator asynchrony
does the management of anastomotic leakage after low rectal resection affect survival

Conditions: Rectal Cancer; Anastomotic Leak

Summary: the aim of this retrospective cohort-study is to assess the effects of al and its severity divided according the isrec-classification on the long-term oncological outcome.

rectal cancer is one of the most common malignancies in the world. its costs and cancer-related mortality are increasing worldwide. the surgical treatment was revolutionized in recent years by the total mesorectal excision (tme) technique as well as the laparoscopic, robotic, and transanal approach. but anastomotic leakage (al) remains one of the most feared complications after low rectal resection regarding postoperative morbidity and mortality as well as functional outcome. several risk factors causing al like low level of anastomosis, large tumor mass, male gender, smoking, perioperative bleeding, and preoperative radio-chemotherapy are known. protective ileo- or colostomy formation and transanal tube placement may decrease the risk of al and reduces the rate of reoperation due to al. diverting results of the association between al and the long-term oncological outcome (local recurrence, systemic recurrence, survival) are described in the current literature. the international study group of rectal cancer (isrec) provides a classification of al according to its clinical management: * grade a results in no change in patient's management * grade b requires active therapeutic intervention without re-laparotomy * grade c requires re-laparotomy this classification allows a good stratification regarding postoperative morbidity and mortality. however, the association between the isrec-classification of al and the long-term oncological outcome is not yet clear.

Eligibility criteria:
inclusion criteria: * patients receiving elective low anterior resection (lar) between february 1991 and december 2020 at the cantonal hospital of st. gallen exclusion criteria: * other diagnosis than rectal cancer * discontinuity resection (no anastomosis) * emergency situation * r1-resection * incomplete staging * metastatic cancer * 30-day mortality * decline of a retrospective data analysis * secondary malignancy * age under 18 years

Keywords: rectal cancer low rectal resection anastomotic leakage isrec-classification cancer-specific survival propensity score
effect of tdcs of the motor cortex on chemotherapy induced nausia and vomiting

Conditions: Chemotherapy-induced Nausea and Vomiting

Summary: this work is looking for the effect of tdcs of the motor cortex on the chemotherapy induced nausea and vomiting in cancer breast patients

chemotherapy has played an important role in improving patient outcomes in oncology and is a cornerstone of therapy for most patients with cancer. of the adverse effects, none is more feared than chemotherapy-induced nausea and vomiting (cinv). nausea and vomiting can adversely affect patients' quality of life and make it difficult for them to perform their activities of daily living. uncontrolled cinv can give rise to medical complications, including poor nutrition, dehydration, electrolyte imbalances, and physical and mental deterioration.the introduction and development of antiemetic drugs have significantly improved the ability of clinicians to control cinv. the mainstays of antiemetic therapy include serotonin (5-ht3) receptor antagonists (ras) and neurokinin 1 (nk-1) ras. researchers and patients are seeking additional methods of controlling cinv, such as non-drug therapies. transcranial direct current stimulation (tdcs) is a relatively simple technique requiring only a few parts.

Eligibility criteria:
inclusion criteria: * breast cancer therapy receiving anthracyclin based adjuvant chemotherapy and prophylaxis against nausea and vomiting exclusion criteria: * patients with intracranial metallic devices or with pacemakers or any other device. * patients with extensive myocardial ischemia * patients known to have epilepsy patients refusal.

Keywords: brain stimulation, tdcs, nausea and vomiting
aponermin, pomalidomide, dexamethasone for patients with relapsed/ refractory multiple myeloma

Conditions: Multiple Myeloma, Neoplasms

Summary: this study aims to evaluate the efficacy and safety of a three drug combination therapy of aponermin, pomalidomide, and dexamethasone in the treatment of relapsed or refractory multiple myeloma


Eligibility criteria:
inclusion criteria: 1. rrmm patients who have received 1-3 line treatment; 2. age above 18 years old, male or female not limited; 3. ecog score ≤ 2; 4. expected survival period is greater than 3 months; 5. for female patients, (1) they have been menopausal for at least 24 months before the screening visit, or have undergone surgical contraception; (2) women with fertility must have two negative urine hcg pregnancy tests within 72 hours before starting to take the study drug; for male patients must agree to absolute abstinence or effective barrier contraception throughout the entire study treatment period until 28 days after the last study drug treatment, and have no sperm donation behavior; 6. the patient understands the purpose and steps of this trial, voluntarily participates in this trial, and signs a written informed consent form. exclusion criteria: 1. allergic or intolerant to the investigational drug or its components; 2. received any experimental drug treatment within 4 weeks; 3. simultaneously suffering from other tumors, or having undergone anti-tumor treatment (including major surgery) in the past 4 weeks; 4. currently, there are poorly controlled heart diseases, such as heart function grade iii or iv (nyah classification),uncontrolled atrial fibrillation, unstable angina, and myocardial infarction within the 12 months prior to enrollment; 5. suffering from mental illness; 6. accompanied by severe lung infection, skin and soft tissue infection, or urinary tract infection; 7. there was a serious thrombotic event before treatment; 8. unable or unwilling to receive prophylactic antithrombotic therapy; 9. serious, uncontrolled medical disorders or active infections; 10. researchers determine situations that are not suitable for inclusion.
the uhsm cardiovascular magnetic resonance study

Conditions: Cardiovascular Diseases

Summary: this study aims to investigate the diagnostic and prognostic utility of cardiovascular magnetic resonance (cmr) imaging in a large cohort of unselected patients who are undergoing cmr scanning for clinical indications (i.e. suspected/confirmed cardiovascular disease). cmr indices will be related to the presence and severity of cardiovascular disease and other markers of cardiovascular and health status.

patients will undergo cmr scanning in the usual clinical manner. as part of the study, patients will undergo approximately 5 minutes of extra cmr scanning. cardiovascular anatomical, structural and functional data will be recorded, including data pertaining to myocardial characteristics (e.g. extracellular volume, oedema, fibrosis, infarction, function, perfusion), pericardial disease; valvular disease; vascular structure and function. blood sampling will be performed on the same day as cmr scanning for assessment of serum/plasma markers of cardiovascular disease and health status, and dna analysis. health questionnaires will be completed on the day of cmr scanning. follow-up information regarding health status, demographics and concurrent medical conditions and treatments will be obtained over a 10 year period following cmr scanning.

Eligibility criteria:
inclusion criteria: any adult patient undergoing clinically indicated cmr scanning at the uhsm cmr unit. exclusion criteria: age \< 18 years, imprisonment, inability to provide informed consent.
when and why desarda repair

Conditions: Inguinal Hernia

Summary: one of the most significant subjects studied in abdominal wall surgery is inguinal hernia. its management is very codified. the main factors evaluating efficient hernia surgery are not only the rate of complications (recurrence and groin pain essentially) but also cost and time to return to normal activities. desarda technique is a non-mesh technique described first in 2001. this surgical technique uses a flap of external oblique aponeurosis in place of a mesh. its singularity remains its low cost, no use of mesh, and less extensive dissection mesh repair has its own limitations; it is unphysiological as mesh is used. chronic inguinal pain, seroma formation, foreign body sensation, risk of mesh infection are common complications and not recommended in strangulated hernias and extra cost involved by the mesh itself. it involves use of undetached strip of external oblique aponeurosis to strengthen the posterior wall of the inguinal canal which is based on the physiological principles. this is a physiological repair and is tension free, can be used in strangulated hernia. recurrence and complication rates equal to or less than lichtenstein's repair. it's a simple procedure, early ambulation and less time of hospital stay, low cost for the patient as mesh is not used and most importantly no question of mesh related complications such as mesh rejection, infection, migration and foreign body sensation and chronic groin pain which is comparatively low in this procedure.


Eligibility criteria:
inclusion criteria: * primary inguinal hernia * aged 18 and above * reducible inguinal or inguino-scrotal hernia exclusion criteria: * obstructive uropathy or chronic obstructive pulmonary disease * incarcerated hernia * recurrent hernia * bilateral hernia * active infection at groin area * pantalloon hernia
the effect of the mini-pill on blood factors in women at increased risk for forming blood clots

Conditions: Women's Health; Blood Coagulation Disorders

Summary: we propose a prospective cohort study to assess the effect of the progesterone only contraceptive pill (minipill) on coagulation parameters known to be associated with risk of thrombosis (blood clots) in women who are at increased risk for forming blood clots. we plan to recruit women with a history of venous thromboembolism (vte, blood clot in a vein) and women with a history of blood tests which demonstrate an increased risk of thrombosis who desire contraception. women enrolled in this study will undergo phlebotomy (blood draw) at baseline (prior to starting the minipill), one and three months. stored samples will be used to measure d-dimer, c-reactive protein (crp), antithrombin (at), factor viii, free and total protein s, fibrinogen, von willebrand factor (vwf) and normalized activated protein c sensitivity ratio (napcsr). both groups will undergo a general physical and gyn exam prior to enrollment. this exam and the blood testing will be provided free of charge. patients will not be prescribed the minipill after completion of the study and will be advised to consult with their primary care physician or hematologist if they wish to continue this medication.


Eligibility criteria:
inclusion criteria: * women with a history of venous thromboembolism (vte, blood clot in a vein) and women with a history of blood tests which demonstrate an increased risk of thrombosis who desire contraception. * blood tests which demonstrate an increased risk of thrombosis include the following: * hyperhomocysteinemia/mthfr mutation * prothrombin gene mutation * factor v leiden heterozygotes * factor v leiden homozygotes, antithrombin iii mutation * protein s deficiency and protein c deficiency. exclusion criteria: * women on current anticoagulation therapy * women with a history of oral contraceptive related thrombotic events * active or history of cigarette smoking within the past 6 months * pregnancy * active lactation * known hypersensitivity to progestin * any history of malignancy * history within the last three months of surgery or planning surgery during the study period * undiagnosed vaginal bleeding * active liver disease and history within the last 5 years of alcoholism or drug abuse. * additionally, women must be greater than 3 months postpartum and have had two months without contraceptive hormones (such as the birth control pill) and 6 months without depo-provera use prior to enrollment.
a clinical study with tremelimumab as monotherapy in malignant mesothelioma

Conditions: Malignant Mesothelioma

Summary: the study is designed to define the immunologic and clinical activity of tremelimumab in patients with advanced mesothelioma.

no effective standard treatment can improve significantly the prognosis of malignant mesothelioma (mm) patients. however, there is evidence that mm patients may benefit from immunotherapeutic agents. clinical studies examining ctla-4 blockade are providing convincing evidences on the immunobiological effects and on the clinical activity of this new class of immunomodulating therapeutic agents, likely due to their ability to stimulate patients'immune system to more effectively attack tumor cells by blocking a negative regulatory signal. tremelimumab is a fully human anti-ctla-4 monoclonal antibody (mab), developed as an igg2 isotype to minimize complement activation and reduce the risk of cytokine storm. as a single agent, tremelimumab can induce durable tumor regression in 7-10% of patients with advanced melanoma. tremelimumab has been tested in several clinical trials as single-agent or in combination with other agents in different solid tumors. the evidences above unveil a strong immunologic potential of treatment with tremelimumab also in mm patients.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed malignant mesothelioma (mm) * have received only one prior systemic chemotherapy platinum-based regimen for advanced mm * disease not amenable to curative surgery * no known brain metastasis * age 18 and over * performance status 0-2 * life expectancy \> 12 weeks * adequate hematologic, hepatic and renal function * not pregnant or nursing * patient must be willing and able to provide written informed consent, and the trial have to be approved by the institutional review board at each institution exclusion criteria: * symptomatic chronic inflammatory or autoimmune disease * active hepatitis b or c * clinically relevant cardiovascular disease, i.e., myocardial infarction or other severe coronary artery diseases within the prior 6 months, cardiac arrythmia requiring medication, uncontrolled hypertension, overt cardiac failure or not compensated chronic heart disease in nyha class ii or more * history of psychiatric disabilities, potentially interfering with the capability of giving adequate informed consent * uncontrolled active infections * other concurrent chemotherapy, immunotherapy, radiotherapy or investigational agents * history of other malignancies except for adequately treated basal cell carcinoma or squamous cell skin cancer or carcinoma of cervix, unless the patient has been disease-free for at least 5 years

Keywords: tremelimumab malignant mesothelioma anti-ctla-4 mab
a study to investigate the effect of triferic plus heparin infusion compared to heparin alone on coagulation parameters in hemodialysis patients

Conditions: End Stage Renal Disease

Summary: this study will investigate the effect of co-administration of triferic and heparin on the ability to maintain circuit anti-coagulation and iron delivery when compared to control conditions when each treatment is administered via separate routes.


Eligibility criteria:
inclusion criteria: 1. adult hemodialysis patients ≥18 years of age. 2. signed informed consent to participate in the study. 3. stable on hemodialysis prescription for ≥3 months. 4. hemoglobin concentration \>9.5 g/dl. 5. serum tsat ≥20%. 6. able to receive continuous heparin infusion as their anticoagulation protocol. 7. receiving hemodialysis via av (arteriovenous) fistula or graft. 8. able to receive hemodialysis for 4 hours at each session over the duration of the treatment periods. exclusion criteria: 1. active bleeding disorder (gi, skin, nasal...) 2. receiving hemodialysis via catheter. 3. receiving heparin free dialysis. 4. receiving low molecular weight heparin as sole anti-coagulation for dialysis. 5. receiving iv iron within 2 weeks of the first on-study hemodialysis treatment. 6. receiving oral anti-coagulants or anti-platelet agents. 7. any other condition, that in the opinion of the investigator would not allow completion of the 3 hemodialysis treatments in the study.
cardiac biomarkers and analytical methods

Conditions: Cardiovascular Diseases; Myocardial Injury

Summary: in the western world the prevalence of myocardial infarction is estimated at around 1-2% of the population; increases progressively with age, reaching a percentage of 10% after the 75 years. it is therefore considered the first cause of hospitalization and mortality in western countries, as well as expenditure for the health system. it is therefore very important to have cardiac biomarkers that allow to confirm the diagnostic suspicion of coronary heart disease and/or heart failure, carry out prognostic evaluations and stratify patients as precisely as possible in relation to their actual risk. currently as biomarkers of heart failure, natriuretic peptides (bnp and nt-probnp) are widely used in clinical practice but, considering the complexity of heart failure and its clinical and pathophysiological heterogeneity, it is reasonable to think that a single biomarker is not sufficient . for these reasons, there is increasing interest in the scientific community in the search for new biomarkers useful for early diagnosis, for correct prognostic stratification and for evaluating the response to therapy.

the study aims to evaluate the analytical performance of different kits and molecular markers commercially available (or in pre-industrial development phase) for the assays of the cardiac biomarkers: ctni , nt-probnp and sst2. 500 samples (residual serum) from patients hospitalized and/or referred to the dea department, for which troponin and/or nt-probnp tests have been requested routinely or urgently by clinicians, will be included in the study. the analytical performance of the various kits and the intra- and interassay imprecision will be evaluated. comparison of methods will be calculated by passing-bablok regression and graph by bland-altman. through the non-parametric passing-bablok model the obtained data will be compared with the various analytical methods, reporting them one in function of the other, together with the regression line. from the regression equation, the proportional systematic error will be evaluated as angular coefficient of the straight line and the constant systematic error as an intercept of the equation

Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * patients arriving in the emergency room with chest pain of presumable cardiac origin and uncertain etiological diagnosis * routine request for cardiac troponin and nt-probnp exclusion criteria: * age \<18 years; * no requirement for cardiac troponin and nt-probnp

Keywords: troponin sst2 nt-probnp laboratory assay